Correlation of plasma miRNAs levels with atrial fibrillation in patients with acute cerebral infarction in early stage

doi:10.16150/j.1671-2870.2017.01.019

Abstract

Abstract: Objective: To investigate the correlation between the plasma miRNAs levels and atrial fibrillation (AF) in patients with acute cerebral infarction in early stage. Methods: Seven hundred and one patients with acute cerebral infraction addmitted in Gongli Hospital during Jan. 2014 to Nov. 2016 were enrolled, and patients were divided into two groups: group with AF(70 cases) and group without AF (631 cases), and 65 healthy cases were served as controls. Clinical data and miRNAs levels between the 3 groups were analyzed, and miRNAs levels were also compared between paroxysmal and persistent AF. Multivariate regression analysis was used to determine the contribution of plasma miRNAs variables to the presence of atrial fibrillation in patients with cerebral infarction in early stage. Results: Plasma levels of miR-328, miR-29b and miR-150 differed significantly between group with AF, group without AF and control group (P<0.05, P<0.01). Different from miR-328 and miR-150, plasma level of miR-29b in cerebral infarction patients with paroxysmal AF was significantly lower than those in group without AF and controls (P<0.01). Logistic regression analysis showed that the specific miRNAs, miR-328, miR-29b and miR-150 were significantly associated with AF and miR-29b was significantly related to paroxysmal AF in patients with acute cerebral infarction. Conclusions: Levels of some specific plasma miRNAs, especially the miR-29b level might be used as predictor for the existing of AF in patients with acute cerebral infraction in early stage.

Key words: Acute cerebral infarction, Atrial fibrillation, MicroRNAs

CLC Number:

R743.33

HU Rongguo, PANG Defang, HUANG Shu, SHEN Zhenkun, CHEN Wei, YANG Yuwei, LAI Xiaoyin, ZHU Wei, WU Feifei, JI Haifeng, WU Dayu, JIANG Mei, SUN Jialan, LI Longxuan. Correlation of plasma miRNAs levels with atrial fibrillation in patients with acute cerebral infarction in early stage[J]. Journal of Diagnostics Concepts & Practice, 2017, 16(01): 98-103.

References

[1] Murakoshi N, Aonuma K.Epidemiology of arrhythmias and sudden cardiac death in Asia[J]. Circ J,2013,77(10):2419-2431.
[2] Tse HF, Wang YJ, Ahmed Ai-Abdullah M, et al. Stroke prevention in atrial fibrillation--an Asian stroke perspective[J]. Heart Rhythm,2013,10(7):1082-1088.
[3] Hohnloser SH, Pajitnev D, Pogue J, et al.Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy[J]. J Am Coll Cardiol,2007,50(22):2156-2161.
[4] Flint AC, Tayal AH.The search for paroxysmal atrial fi-brillation in cryptogenic stroke: leave no stone unturned[J]. Neurology,2013,80(17):1542-1543.
[5] King A.Atrial fibrillation: Could subclinical AF be a missing link in the etiology of cryptogenic stroke?[J]. Nat Rev Cardiol,2012,9(3):126.
[6] Manina G, Agnelli G, Becattini C, et al.96 hours ECG monitoring for patients with ischemic cryptogenic stroke or transient ischaemic attack[J]. Intern Emerg Med,2014, 9(1):65-67.
[7] Sanna T, Diener HC, Passman RS, et al.Cryptogenic stroke and underlying atrial fibrillation[J]. N Engl J Med,2014,370(26):2478-2486.
[8] Moubarak G, Tamazyan R, Garcon P, et al.Detection of occult atrial fibrillation by pacemaker interrogation in cryptogenic stroke[J]. J Interv Card Electrophysiol,2014, 39(3):261-265.
[9] Baibars M, Kanjwal K, Marine JE.AF detected on implanted cardiac implantable electronic devices: is there a threshold for thromboembolic risk?[J]. Curr Treat Options Cardiovasc Med,2014,16(3):289.
[10] Wang X, Qiu CG, Huang ZW, et al.The expression and clinical implication of plasma miR-328 in patients with atrial fibrillation[J]. Zhonghua Xin Xue Guan Bing Za Zhi,2013,41(2):126-129.
[11] Dawson K, Wakili R, Ordög B, et al. MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation[J]. Circulation,2013,127(14):1466-1475,1475e1-1475e28.
[12] Liu Z, Zhou C, Liu Y, et al.The expression levels of plasma micoRNAs in atrial fibrillation patients[J]. PLoS One,2012,7(9):e44906.
[13] 彭彬, 吴大玉, 孙家兰, 等. 急性脑梗死早期血中miRNAs水平与脑侧支循环建立的关系[J]. 中风与神经疾病杂志,2016,33(2):100-103.
[14] Lu Y, Zhang Y, Wang N, et al.MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation[J]. Circulation,2010,122(23):2378-2387.
[15] McManus DD, Lin H, Tanriverdi K, et al. Relations between circulating microRNAs and atrial fibrillation: data from the Framingham Offspring Study[J]. Heart Rhythm,2014,11(4):663-669.
[16] Small EM, Olson EN.Pervasive roles of microRNAs in cardiovascular biology[J]. Nature,2011,469(7330):336-342.
[17] de Boer HC, van Solingen C, Prins J, et al. Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease[J]. Eur Heart J,2013,34(44):3451-3457.
[18] Wang Y, Huang J, Ma Y, et al.MicroRNA-29b is a thera-peutic target in cerebral ischemia associated with aquaporin 4[J]. J Cereb Blood Flow Metab,2015,35(12):1977-1984.
[19] Khanna S, Rink C, Ghoorkhanian R, et al.Loss of miR-29b following acute ischemic stroke contributes to neural cell death and infarct size[J]. J Cereb Blood Flow Metab,2013,33(8):1197-1206.
[20] Llombart V, Garcia-Berrocoso T, Bustamante A, et al.Cardioembolic stroke diagnosis using blood biomarkers[J]. Curr Cardiol Rev,2013,9(4):340-352.
[21] McManus DD, Tanriverdi K, Lin H, et al. Plasma microRNAs are associated with atrial fibrillation and change after catheter ablation(the miRhythm study)[J]. Heart Rhythm,2015,12(1):3-10.